Elevated Serum Iron Levels following Administration of Cisplatinum

Publisher Website
Google Scholar
Abstract
An increase in serum iron levels and a decrease in serum unsaturated iron binding capacity (uIBC) were noted following the administration of cisplatinum to 9 children with malignancies. The mean serum iron concentration increased from a pretreatment level of 75.7 .+-. 30.5 .mu.g/ml to a posttreatment level of 162.1 .+-. 65.3 .mu.g/ml with the first cisplatinum treatment course (p < 0.004). The uIBC concomitantly decreased from 181.9 .+-. 33.7 .mu.g/ml to 86.4 .+-. 44.6 .mu.g/ml (p < 0.0005). A cumulative effect was noted following subsequent courses. The levels returned to baseline values within 2-4 months following cessation of therapy in 6 children in whom follow-up data were available. It is possible that this reversal of the iron/uIBC ratio is the result of cisplatinum competition for iron binding sites to proteins.

This publication has 2 references indexed in Scilit: